These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Suitability of [18F]altanserin and PET to determine 5-HT2A receptor availability in the rat brain: in vivo and in vitro validation of invasive and non-invasive kinetic models. Kroll T; Elmenhorst D; Matusch A; Wedekind F; Weisshaupt A; Beer S; Bauer A Mol Imaging Biol; 2013 Aug; 15(4):456-67. PubMed ID: 23456885 [TBL] [Abstract][Full Text] [Related]
29. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Biver F; Goldman S; Luxen A; Monclus M; Forestini M; Mendlewicz J; Lotstra F Eur J Nucl Med; 1994 Sep; 21(9):937-46. PubMed ID: 7995287 [TBL] [Abstract][Full Text] [Related]
30. A PET [18F]altanserin study of 5-HT2A receptor binding in the human brain and responses to painful heat stimulation. Kupers R; Frokjaer VG; Naert A; Christensen R; Budtz-Joergensen E; Kehlet H; Knudsen GM Neuroimage; 2009 Feb; 44(3):1001-7. PubMed ID: 19007894 [TBL] [Abstract][Full Text] [Related]
31. Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Bailer UF; Price JC; Meltzer CC; Mathis CA; Frank GK; Weissfeld L; McConaha CW; Henry SE; Brooks-Achenbach S; Barbarich NC; Kaye WH Neuropsychopharmacology; 2004 Jun; 29(6):1143-55. PubMed ID: 15054474 [TBL] [Abstract][Full Text] [Related]
32. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Meltzer CC; Price JC; Mathis CA; Greer PJ; Cantwell MN; Houck PR; Mulsant BH; Ben-Eliezer D; Lopresti B; DeKosky ST; Reynolds CF Am J Psychiatry; 1999 Dec; 156(12):1871-8. PubMed ID: 10588399 [TBL] [Abstract][Full Text] [Related]
34. Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT. Beauregard JM; Croteau E; Ahmed N; van Lier JE; Bénard F J Nucl Med; 2009 Jan; 50(1):100-7. PubMed ID: 19091905 [TBL] [Abstract][Full Text] [Related]
35. Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans. Matusch A; Hurlemann R; Rota Kops E; Winz OH; Elmenhorst D; Herzog H; Zilles K; Bauer A J Neural Transm (Vienna); 2007; 114(11):1433-42. PubMed ID: 17541696 [TBL] [Abstract][Full Text] [Related]
37. Kinetic analysis of [ Pauwelyn G; Vlerick L; Dockx R; Verhoeven J; Dobbeleir A; Bosmans T; Peremans K; Vanhove C; Polis I; De Vos F BMC Vet Res; 2019 Nov; 15(1):415. PubMed ID: 31752848 [TBL] [Abstract][Full Text] [Related]
38. Measurement of changes in endogenous serotonin level by positron emission tomography with [ Ikoma Y; Takuwa H; Nishino A; Maeda J; Kawamura K; Obata T; Zhang MR; Higuchi M; Suhara T Ann Nucl Med; 2021 Aug; 35(8):955-965. PubMed ID: 34101154 [TBL] [Abstract][Full Text] [Related]
39. Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. Liptrot M; Adams KH; Martiny L; Pinborg LH; Lonsdale MN; Olsen NV; Holm S; Svarer C; Knudsen GM Neuroimage; 2004 Feb; 21(2):483-93. PubMed ID: 14980551 [TBL] [Abstract][Full Text] [Related]
40. In vivo evaluation in rodents of [(123)I]-3-I-CO as a potential SPECT tracer for the serotonin 5-HT(2A) receptor. Blanckaert PB; Burvenich I; Wyffels L; De Bruyne S; Moerman L; De Vos F Nucl Med Biol; 2008 Nov; 35(8):861-7. PubMed ID: 19026947 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]